Literature DB >> 19494223

Unorthodox approach to the development of a new antituberculosis therapy.

Clifton E Barry.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19494223      PMCID: PMC2787472          DOI: 10.1056/NEJMe0903012

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  6 in total

Review 1.  Drugs for bad bugs: confronting the challenges of antibacterial discovery.

Authors:  David J Payne; Michael N Gwynn; David J Holmes; David L Pompliano
Journal:  Nat Rev Drug Discov       Date:  2006-12-08       Impact factor: 84.694

2.  Early bactericidal activity of high-dose rifampin in patients with pulmonary tuberculosis evidenced by positive sputum smears.

Authors:  A H Diacon; R F Patientia; A Venter; P D van Helden; P J Smith; H McIlleron; J S Maritz; P R Donald
Journal:  Antimicrob Agents Chemother       Date:  2007-05-21       Impact factor: 5.191

3.  The diarylquinoline TMC207 for multidrug-resistant tuberculosis.

Authors:  Andreas H Diacon; Alexander Pym; Martin Grobusch; Ramonde Patientia; Roxana Rustomjee; Liesl Page-Shipp; Christoffel Pistorius; Rene Krause; Mampedi Bogoshi; Gavin Churchyard; Amour Venter; Jenny Allen; Juan Carlos Palomino; Tine De Marez; Rolf P G van Heeswijk; Nacer Lounis; Paul Meyvisch; Johan Verbeeck; Wim Parys; Karel de Beule; Koen Andries; David F Mc Neeley
Journal:  N Engl J Med       Date:  2009-06-04       Impact factor: 91.245

Review 4.  Developing new drugs for the treatment of drug-resistant tuberculosis: a regulatory perspective.

Authors:  Leonard V Sacks; Rachel E Behrman
Journal:  Tuberculosis (Edinb)       Date:  2008-08       Impact factor: 3.131

5.  PA-824 kills nonreplicating Mycobacterium tuberculosis by intracellular NO release.

Authors:  Ramandeep Singh; Ujjini Manjunatha; Helena I M Boshoff; Young Hwan Ha; Pornwaratt Niyomrattanakit; Richard Ledwidge; Cynthia S Dowd; Ill Young Lee; Pilho Kim; Liang Zhang; Sunhee Kang; Thomas H Keller; Jan Jiricek; Clifton E Barry
Journal:  Science       Date:  2008-11-28       Impact factor: 63.714

6.  Randomized trials to optimize treatment of multidrug-resistant tuberculosis.

Authors:  Carole D Mitnick; Kenneth G Castro; Mark Harrington; Leonard V Sacks; William Burman
Journal:  PLoS Med       Date:  2007-11-06       Impact factor: 11.069

  6 in total
  4 in total

Review 1.  The chemical biology of new drugs in the development for tuberculosis.

Authors:  Clifton E Barry; John S Blanchard
Journal:  Curr Opin Chem Biol       Date:  2010-05-07       Impact factor: 8.822

Review 2.  TMC207: the first compound of a new class of potent anti-tuberculosis drugs.

Authors:  Alberto Matteelli; Anna Cc Carvalho; Kelly E Dooley; Afranio Kritski
Journal:  Future Microbiol       Date:  2010-06       Impact factor: 3.165

Review 3.  New drugs and regimens for treatment of TB.

Authors:  Eric Leibert; William N Rom
Journal:  Expert Rev Anti Infect Ther       Date:  2010-07       Impact factor: 5.091

Review 4.  New drugs to treat multidrug-resistant tuberculosis: the case for bedaquiline.

Authors:  Eric Leibert; Mauricio Danckers; William N Rom
Journal:  Ther Clin Risk Manag       Date:  2014-07-29       Impact factor: 2.423

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.